Small samples
Published alcohol-focused reports involve limited participant numbers. Small samples are especially vulnerable to chance findings and cannot reliably characterize uncommon but serious harms.
Alcohol use disorder · research record
Evidence & Trials
A rigorous, plain-language look at the limited human research and developing clinical pipeline for ibogaine-related interventions in alcoholism—what has been studied, what remains incomplete, and what the evidence cannot yet show.
01 / Start with the record
A narrow evidence base
For alcohol use disorder specifically, human research on ibogaine remains early. The available record includes observational and open-label work, registered studies without public results, and an investigational development program—not a body of large, replicated randomized trials.
Open-label designs
When participants and researchers know what is being given, expectations, concurrent care, and self-selection can all influence reported outcomes.
Safety is central
Ibogaine has documented cardiac risk concerns. An evidence discussion has to keep efficacy questions separate from whether a protocol can be delivered safely.
02 / Completed and registered work
What has actually been studied?
The distinction between a published study, a registry entry, and a proposed program matters. A registry can document a planned trial, but it does not by itself provide outcome data or demonstrate a positive result.
Open-label work in alcohol dependence
Older clinical reports and case-series-style observations have described ibogaine administration among people with alcohol dependence or broader substance-use histories. These reports are useful for identifying questions, but they do not function as definitive comparative trials.
- DesignOpen-label, observational, or uncontrolled pilot reporting.
- SampleSmall and not designed to provide precise efficacy or safety estimates.
- EndpointsGenerally alcohol use, craving, abstinence-related follow-up, and adverse events; outcome definitions and follow-up vary.
- LimitsNo blinded comparator, selection bias, inconsistent co-interventions, and substantial difficulty separating drug effects from setting and aftercare.
- QualityLow certainty for effectiveness. Findings can generate hypotheses, not establish clinical benefit.
Readers comparing different accounts of this literature can use ibogaine hydrochloride context to distinguish the compound discussion from a conclusion about alcoholism outcomes.
Trials listed without published results
Some ibogaine-related studies have been registered or discussed as planned investigations. Where results are not posted in a registry or published in a peer-reviewed paper, there is no outcome dataset to grade.
- DesignProtocol details may be available in a registration record, but implementation and analysis status can differ from the original plan.
- SamplePlanned enrollment is not the same as enrolled, treated, or analyzed participants.
- EndpointsPrimary endpoints should be checked against the original record, including timing and definitions.
- LimitsAbsent results prevent assessment of attrition, protocol changes, adverse events, and effect estimates.
- QualityUngradable until results and methods are publicly available.
The ClinicalTrials.gov registry is a primary place to verify a study’s stated design, recruitment status, and posted results rather than relying on promotional summaries.
Absence of publicly available trial results is not evidence of benefit, harm, or failure. It is a gap in what outside readers can responsibly conclude.
03 / Development pipeline
A regulatory milestone is not approval
Through 2026, the most visible alcohol-focused development milestone is DemeRx’s work on DMX-1001. The company’s IND acceptance is important because it permits investigational clinical development in the United States; it does not show that the product is approved, safe, or effective for alcohol use disorder.
FDA acceptance for DMX-1001
DemeRx has announced FDA acceptance of an Investigational New Drug application for DMX-1001, its ibogaine-related candidate for alcohol use disorder. An IND allows clinical investigation under FDA oversight; it is not marketing authorization.
Early development questions
Early-stage development typically focuses on dose, pharmacokinetics, and safety. It cannot answer the same effectiveness questions as an adequately powered later-stage trial with a meaningful comparator.
Public evidence still determines confidence
Until study protocols, outcomes, adverse events, attrition, and analysis plans are available, the appropriate evidence grade remains preliminary.
04 / Evidence-grade takeaways
What the current record supports
A careful synthesis should be able to say “not known” without filling the gap with certainty. These are evidence-grade conclusions, not treatment recommendations.
Effectiveness
- There is no robust, replicated randomized evidence establishing ibogaine as an effective treatment for alcoholism.
- Open-label findings cannot distinguish a drug effect from expectancy, selection, setting, or concurrent support.
- Long-term alcohol outcomes need consistent definitions, adequate follow-up, and transparent reporting.
Safety
- Cardiac risk is a serious concern in ibogaine discussions, including risk related to heart-rhythm changes.
- Small studies cannot reliably quantify rare but severe adverse events.
- The general ibogaine reference record is useful background, but primary safety evidence and medical evaluation matter more than summaries.
Decision context
- Alcohol withdrawal can be medically dangerous, and any change in alcohol use warrants appropriate clinical guidance.
- Claims about care outside regulated research should not be treated as substitutes for trial evidence.
- Different legal and care settings do not convert uncertain evidence into established practice.
Questions about treatment availability are separate from questions about research quality. Accounts of ibogaine treatment in Texas or treatment-center settings in Mexico should be assessed carefully without treating location or marketing as evidence of efficacy.
05 / Questions worth asking
Keep the uncertainty visible.
For a broader introduction to the substance itself, see the site’s plain-language ibogaine overview. This page stays focused on the narrower question of alcohol-specific evidence.
Does the current research establish ibogaine as a treatment for alcoholism?
No. The alcohol-specific human evidence is limited, largely small and uncontrolled, and does not establish effectiveness or an acceptable safety profile. The safety considerations for alcohol use belong in the same conversation as any research claim.
What does an IND acceptance for DMX-1001 mean?
It means FDA allowed an investigational program to proceed into clinical study under an IND. It is not FDA approval and does not establish that the drug is safe or effective. The distinction is particularly important when interpreting company announcements.
Can reports in other conditions answer the alcoholism question?
No. Research or claims involving another condition cannot be assumed to apply to alcohol use disorder. For example, material on ibogaine-related Parkinson’s discussions addresses a different clinical question, population, and set of outcomes.
What should a reader verify before trusting a trial claim?
Check whether the study is registered, whether results are public, how many people were analyzed, what outcome was pre-specified, how long follow-up lasted, and how adverse events were reported. A description of an ibogaine treatment is not a substitute for those trial details.
Evidence first. Claims second.
Return to the broader ibogaine and alcohol-use-disorder resource for grounded context, or review how Clear Ember approaches uncertainty in its independent-resource mission.